Merck's Keytruda shines in pre-ASCO abstract release, with Pfizer catching the limelight, too

Keytruda

The ASCO abstracts are out, and they’re a mixed bag for the Big Pharma companies tied up in the PD-1/PD-L1 race. 

The American Society of Clinical Oncology's annual meeting is arguably pharma's most closely watched conference, and industry watchers are always on the lookout for winners--and losers. The way Leerink Partners analysts see it, Merck’s Keytruda is sitting pretty ahead of the conference, to be held in Chicago in early June.

Wednesday, the New Jersey pharma giant released long-term overall survival data for its immunotherapy in melanoma, showing that more than 55% of patients were alive two years after starting treatment, compared with 43% of patients taking Bristol-Myers Squibb’s Yervoy. Release

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

But Merck is also testing the med in different types of cancer and in different combinations; results from the Keynote-021 study, which tested a Keytruda chemo combo in 74 lung cancer patients, showed progression-free survival of 10 months overall, and between 14 and 15 months in PD-L1-positive patients, Leerink’s Seamus Fernandez wrote to clients. And with no new corresponding data on Bristol-Myers Squibb’s Opdivo coming before the conference weekend, Merck’s cocktail is taking “center stage pre-ASCO.”

Pfizer also teamed its own cancer contender with the Merck checkpoint inhibitor to the tune of positive results. Its up-and-comer, utomilumab, showed early promise against a variety of cancer types in a tiny clinical trial, Reuters notes.

Meanwhile, the New York drugmaker is hard at work with partner Merck KGaA on prospect avelumab, and it intends to highlight data on that compound at ASCO, too. Release

But the PD-L1 therapy lags behind others in the checkpoint inhibitor crowd--including FDA breakthrough drug durvalumab from AstraZeneca and Roche’s Tecentriq, which won its first U.S. approval on Thursday in bladder cancer. In that indication, though, AZ’s rival and BMS’ Opdivo showed higher response rates, Fernandez noted. “Baseline characteristics to be presented at ASCO should be closely watched,” he wrote.

Special Report: The biggest winners--and losers--in the 2015 race for new drug approvals

Related Articles:
Roche's Tecentriq bursts onto immuno-oncology scene, with Merck and BMS in its sights
Opdivo gives head and neck cancer patients a shot at 12-month survival​
Merck's Keytruda lines up its survival data for stepped-up battle with BMS' Opdivo
The PD-1 wave? Report says it's a $33B tsunami, with BMS surfing for first place

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.